• D&A Pharma, of Paris, will participate in the 14th Congress of the European Society for Biomedical Research on Alcoholism (ESBRA) in Warsaw Sept. 8-11, with results of trials of Alcover (sodium oxybate) showing that the drug met therapeutic objectives for management of alcohol dependence.